Vaximm AG, a spin-out from Merck KGaA, has appointed Jean-Paul Prieels to its board of directors. Dr Prieels is a former senior vice president for research and development at GlaxoSmithKline Plc where he was instrumental in the development of several vaccines, including Cervarix.
Vaximm is a privately held Swiss-German company that is developing cancer vaccines. It announced the appointment on 3 May 2012.
Copyright 2011 Evernow Publishing Ltd